RDHL · RedHill Biopharma Ltd.
$0.73
+0.03 (+4.29%)
At close · Jul 28
Market Cap
$4.44M
Shares
6.08M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.73
Open$0.72
Day$0.65–0.73
52W$0.64–2.79
Avg vol 30d132K
Short int20K · 0.3% float · 1.0d
Short vol14%
Last earningsMar 31, 2022
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−14%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−17%
trailing
6-month return
−37%
trailing
YTD return
−29%
this year
Relative strength
−44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
3 of 16 funds reported for Jun 30 · net +284 sh shares
Insider flow
Distributing
Net -$1.4K over 90 days · 100% sells
Short interest
Falling
0.33% of float · ▼ -35.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
16 holders — mid 1-yr range
Squeeze score
26
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
9.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
3 of 16 funds reported for Jun 30 · net +284 sh shares
Insider flow
Distributing
Net -$1.4K over 90 days · 100% sells
Short interest
Falling
0.33% of float · ▼ -35.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
16 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 4%
52-wk high $3
vs 200-day avg -31%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RDHL
this stock
RedHill Biopharma Ltd.
|
$4.44M | -29.1% | — | — | 0.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$55.95B | +12.4% | — | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
GALDY
Galderma Group AG/ADR
|
$50.49B | +4.5% | — | — | 0.0% |
|
HLN
Haleon plc
|
$45.23B | +1.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
16
- % held
- 8.5%
- Reported
- 3 of 16
- Top holder
- Yorkville Advisors Global…
Held
Float
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RDHL | +4.3% | -17.0% | -36.5% | -13.6% | -29.1% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +5.3% | -16.9% | -44.0% | -12.8% | -37.8% |